Armata Pharmaceuticals Inc ARMP

ASE: ARMP | ISIN: US04216R1023   30/04/2025
1,590 USD (+3,92%)
(+3,92%)   30/04/2025

23 mei 2022 · Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus · Persbericht

12 mei 2022 · Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update · Persbericht

31 maart 2022 · Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva · Persbericht

17 maart 2022 · Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides Corporate Update · Persbericht

22 februari 2022 · Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis · Persbericht

17 februari 2022 · Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences · Persbericht

9 februari 2022 · Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development · Persbericht

5 januari 2022 · Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs · Persbericht

18 november 2021 · Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Progress Across Key Phage Therapeutic Development Programs · Persbericht

10 november 2021 · Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate Update · Persbericht

4 november 2021 · Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress · Persbericht

2 november 2021 · Armata Enters Lease to Build State-of-the-Art R&D and GMP Manufacturing Facility · Persbericht

29 oktober 2021 · Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals · Persbericht

8 september 2021 · Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference · Persbericht

12 augustus 2021 · Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update · Persbericht

2 augustus 2021 · Armata Pharmaceuticals Announces Chief Executive Officer Transition · Persbericht

7 juli 2021 · Armata Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference · Persbericht

13 mei 2021 · Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update · Persbericht

18 maart 2021 · Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update · Persbericht

17 maart 2021 · Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva · Persbericht

Mijn selecties